FDA Approves First Iron-Based Contrast Agent for Brain MRI Imaging
Key Insights
The FDA has approved Ferabright (search) (ferumoxytol injection), the first iron-based contrast agent specifically indicated for brain MRI imaging in adults with known or suspected malignant brain neoplasms.
Clinical trials demonstrated that Ferabright (search)-enhanced MRI significantly improved visualization of primary and secondary brain neoplasms compared to pre-contrast imaging.
The agent offers advantages including an extended imaging window due to its long half-life, suitability for patients with renal insufficiency (search), and processing through natural iron metabolism pathways.
The U.S. Food and Drug Administration has approved Ferabright (search) (ferumoxytol injection), marking a significant milestone as the first iron-based contrast agent specifically indicated for magnetic resonance imaging of the brain in adults with known or suspected malignant neoplasms (search). The approval, announced by Azurity Pharmaceuticals (search) on October 17, 2025, addresses a critical need for alternative contrast agents in neuroimaging.
Enhanced Imaging Performance
In clinical trials, Ferabright (search)-enhanced MRI demonstrated significantly improved visualization of primary and secondary brain neoplasms compared with pre-contrast imaging. The agent is engineered as an advanced superparamagnetic iron oxide nanoparticle contrast agent designed for high relaxivity, which significantly enhances image contrast and precision in brain tumor (search) delineation compared to non-contrast MRI.
"Ferumoxytol expands our MRI toolkit and provides an option for patients who are either contraindicated for or decline gadolinium," said Csanad Varallyay, MD, PhD, a neuroradiologist based in Portland, Oregon, with longstanding research experience in ferumoxytol-enhanced MRI.
Clinical Advantages and Safety Profile
Ferabright (search) offers several distinct advantages over traditional contrast agents. The drug features an extended imaging window due to its long half-life, which may support flexible MRI protocols without the need for multiple contrast administrations. As an iron-based agent, Ferabright is processed through the body's natural iron metabolism pathways, potentially reducing concerns related to long-term retention associated with other contrast agents.
Unlike many other contrast agents, Ferabright (search) is suitable for patients with renal insufficiency (search), enabling access to contrast-enhanced MRI while reducing exposure to heavy metals found in other contrast agents. This addresses a significant clinical need for patients with compromised kidney function who require brain imaging.
Administration and Safety Considerations
Ferabright (search) will be supplied in single-dose vials of 300 mg elemental iron per 10 mL (30 mg/mL) and 510 mg elemental iron per 17 mL (30 mg/mL) for intravenous infusion over at least 15 minutes. The drug carries a black box warning for anaphylaxis (search) and other serious hypersensitivity reactions (search), as fatal and serious hypersensitivity reactions, including anaphylaxis, have occurred in patients receiving ferumoxytol products.
In clinical studies, hypersensitivity reactions (search) were reported in 0.4% of patients administered ferumoxytol as an intravenous infusion over at least 15 minutes. The most common adverse reactions (≥0.65%) include nausea, pruritus, constipation, headache, diarrhea, increased blood pressure, bleeding, hyperpigmentation, vein injury, taste alteration, burning/tingling sensation with injection, red sclera, allergic rhinitis, back pain, vomiting, and increased ALT.
Impact on MRI Protocols
Healthcare providers should be aware that MRI obtained with Ferabright (search) may demonstrate different size, intensity, and pattern of contrast signal in lesions compared to images obtained with gadolinium-based contrast. Administration of Ferabright may transiently affect the diagnostic ability of MRI, with alterations potentially persisting for up to 3 months following the dose.
"Ferabright (search) is an advanced superparamagnetic iron oxide nanoparticle contrast agent engineered for high relaxivity," said Ronald Scarboro, CEO of Azurity Pharmaceuticals (search). "It significantly enhances image contrast and precision in brain tumor (search) delineation compared to non-contrast MRI, offering clinicians a new tool for diagnostic imaging and improved patient care."
The approval represents a significant advancement in neuroimaging, particularly for patients who cannot receive gadolinium-based contrast agents due to contraindications or personal preference, expanding diagnostic options in brain tumor (search) evaluation.